Cargando…

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer

Tamoxifen(TAM) is one of the most effective endocrine treatment for estrogen receptor(ER)-positive breast cancer, however drug resistance greatly limits benefit of it. Our purpose is to uncover the role of Beclin 1 in tamoxifen resistance and prognosis of ER positive breast cancer. We established a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Yu, Chen, Tianxiang, Li, Guangliang, Xu, Cong, Xu, Zhenzhen, Zhang, Jing, He, Kuifeng, Zheng, Linyan, Guan, Zhonghai, Su, Xinyun, Cao, Jiang, Teng, Lisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581020/ https://www.ncbi.nlm.nih.gov/pubmed/28881721 http://dx.doi.org/10.18632/oncotarget.11044

Ejemplares similares

LncRNA UCA1 in anti-cancer drug resistance
por: Wang, Haohao, et al.
Publicado: (2017)

ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
por: Li, Guangliang, et al.
Publicado: (2020)

Giant appendiceal neurofibroma in von Recklinghausen’s disease: A case report and literature review
por: GUO, LIWEN, et al.
Publicado: (2014)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
por: Lu, Jun, et al.
Publicado: (2015)

ER-α36: a novel biomarker and potential therapeutic target in breast cancer
por: Su, Xingyun, et al.
Publicado: (2014)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases
por: Jin, Ketao, et al.
Publicado: (2011)

Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target
por: Du, Xiaoxiao, et al.
Publicado: (2020)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Advances in the targeted therapy of liposarcoma
por: Guan, Zhonghai, et al.
Publicado: (2015)

Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways
por: Wang, Haiyong, et al.
Publicado: (2017)

COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2019)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

NFATc2-dependent epigenetic downregulation of the TSC2/Beclin-1 pathway is involved in neuropathic pain induced by oxaliplatin
por: Liu, Meng, et al.
Publicado: (2023)

Downregulation of Beclin1 and Impairment of Autophagy in a Small Population of Colorectal Cancer
por: Chen, Zhihong, et al.
Publicado: (2013)

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend
por: Zhang, Jing, et al.
Publicado: (2020)

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
por: Lindberg, Karolina, et al.
Publicado: (2011)

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells
por: Li, Wei, et al.
Publicado: (2018)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
por: Volpato, Milene, et al.
Publicado: (2020)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

Beclin 1 overexpression inhibits chondrocyte apoptosis and downregulates extracellular matrix metabolism in osteoarthritis
por: Song, Bin, et al.
Publicado: (2017)

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
por: Cockburn, Jessica G., et al.
Publicado: (2016)

Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer
por: Carmassi, Claudia, et al.
Publicado: (2021)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis
por: Xu, Lu, et al.
Publicado: (2021)

ER-Targeted Beclin 1 Supports Autophagosome Biogenesis in the Absence of ULK1 and ULK2 Kinases
por: Anwar, Tahira, et al.
Publicado: (2019)

Downregulation of Claudin5 promotes malignant progression and radioresistance through Beclin1-mediated autophagy in esophageal squamous cell carcinoma
por: Huang, Shan, et al.
Publicado: (2023)

GPRC5A: An Emerging Biomarker in Human Cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
por: Park, B-W, et al.
Publicado: (2005)

Rapamycin-induced miR-30a downregulation inhibits senescence of VSMCs by targeting Beclin1
por: Tan, Pan, et al.
Publicado: (2019)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

Tamoxifen Inhibits ER-negative Breast Cancer Cell Invasion and Metastasis by Accelerating Twist1 Degradation
por: Ma, Gang, et al.
Publicado: (2015)

PI(3)P-bound UVRAG coordinates Golgi-ER retrograde and Atg9 transport by differential interactions with the ER tether and the Beclin1 complex
por: He, Shanshan, et al.
Publicado: (2013)

Autophagy-Related Beclin 1 and Head and Neck Cancers
por: Hu, Yang-Jie, et al.
Publicado: (2020)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
por: Li, Ying, et al.
Publicado: (2020)

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
por: Cittelly, Diana M, et al.
Publicado: (2010)

Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance
por: Feng, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qchd61s6lehthm957535v0uudj